Sutro Biopharma, Inc. (STRO) stock

STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$9.59−0.67 (-6.53%)

Close on Nov 12, 2026Market cap $159.01MP/E –Yield –

Sutro Biopharma pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Sutro Biopharma's pe ratio was 66.8× on Jan 29, 2021.

Period	Period end	Value	Change (pts)
2021	Jan 29, 2021	66.8×	+1.3
2020	Dec 31, 2020	65.5×	–

Parsed from the XBRL in Sutro Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Dec 3, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing